Skip to main content

Treatment Clinical Trials for Melanoma

Review the melanoma treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 101-125 of 184

Neoadjuvant and Adjuvant Anti-PD-L1 Immunotherapy for the Treatment of Locoregionally Advanced Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Combined Immunotherapy with Ipilimumab and Nivolumab or Nivolumab and Relatlimab and Radiation Therapy before Surgery for the Treatment of Sinonasal and Anorectal Melanoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Immunotherapy (Pembrolizumab or Nivolumab) with Metformin or Rosiglitazone for the Treatment of Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Ipilimumab in Combination with Relatlimab and Nivolumab for the First Line Therapy in Patients with Stage III-IV Unresectable or Metastatic Melanoma, TRINITY Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Status: Active
Location: 3 locations
Nivolumab and Hydroxychloroquine or Nivolumab, Ipilimumab, and Hydroxychloroquine for the Treatment of Stage III-IV Melanoma
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Dapansutrile and Pembrolizumab for the Treatment of Refractory or Recurrent Advanced Melanoma, DREAM Study
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Duvelisib in Combination with Nivolumab for Treatment of Unresectable Stage IIIB-IV Melanoma
Status: Active
Location: 2 locations
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Tebentafusp-tebn in Combination with Liver-Directed Therapies (TACE and IE) for the Treatment of Metastatic Uveal Melanoma
Status: Active
Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Lymphodepletion Chemotherapy, CD40L-41BBL-Augmented Tumor Infiltrating Lymphocytes, and Interleukin-2 for the Treatment of Advanced, Unresectable, and Metastatic Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Neratinib and Divalproex Sodium in Treating Patients with Advanced Solid Tumors or RAS-Mutated Cancers
Status: Active
Location: VCU Massey Comprehensive Cancer Center, Richmond, Virginia
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
E7777 and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
RAPA-201 Therapy of Solid Tumors
Status: Active
Location: Hackensack University Medical Center, Hackensack, New Jersey
Genetically Engineered Tumor Infiltrating Lymphocytes (KSQ-004EX) for the Treatment of Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Personalized Neoantigen Peptide-Based Vaccine in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Naltrexone and Propranolol in Combination with Standard of Care Ipilimumab and Nivolumab for the Treatment of Stage II-III Melanoma
Status: Active
Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey